Even if you have previously told us how you would like to hear from us and/or you have supported us for many years, new data protection legislation requires you to provide your explicit consent in order for us to continue to contact you in the ways that are important to you.
Please use this form to tell us your preferences. You can also change your mind at any time – you will find further details about how to do this below. In the future, we will only contact you about the areas of our work you choose via the communication methods you prefer. Please complete all fields.
29.11.19
We are joining 140+ organisations in a call to all political parties to put children and young people at the heart of this General Election...
Read more19.11.19
Kim Stratton, Chief Executive Officer at Orphazyme, commented, “We are delighted with FDA’s decision to grant Breakthrough Therapy Designation to arimoclomol for NPC. Arimoclomol has been shown to have a clinically meaningful effect on disease progression in NPC that is further supported by a biomarker effect indicating an effect on the biological underpinnings of the disease and a favorable safety and tolerability profile. We are committed to bringing this product to patients as soon as possible. Breakthrough Therapy Designation is designed to expedite the development and review of products for serious diseases with the direct involvement of senior staff and we look forward to working closely with the FDA to further advance arimoclomol. Our preparations for filing in the US are underway and we are on track to submit a New Drug Application in H1 2020.”
Read more
